Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2757926 | 0.78 | POLB (0.52) | POLBEPHX1MEN1KMT2ALMNA | |
| SCHEMBL13653080 | 0.76 | POLB (0.50) | POLBEPHX1MEN1KMT2A | |
| SCHEMBL966408 | 0.76 | CYP3A4 (0.37) | POLBTRPA1 | |
| SCHEMBL11017806 | 0.74 | TRPA1 (0.34) | TRPA1LMNA | |
| SCHEMBL10906569 | 0.74 | POLB (0.48) | POLBEPHX1MEN1KMT2ALMNA | |
| SCHEMBL5705014 | 0.74 | POLB (0.48) | POLBEPHX1MEN1KMT2A | |
| SCHEMBL10904081 | 0.72 | POLB (0.46) | POLBEPHX1MEN1KMT2A | |
| SCHEMBL19964564 | 0.70 | POLB (0.45) | POLBEPHX1MEN1KMT2ALMNA | |
| SCHEMBL968850 | 0.70 | TRPA1 (0.33) | TRPA1 | |
| SCHEMBL967474 | 0.70 | ALDH1A1 (0.39) | TRPA1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9284316-B2 | Substituted fused pyrimidine compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2016-03-15 | — | — | US | disclosed |
| US-20150087643-A1 | Substituted Fused Pyrimidine Compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2015-03-26 | — | — | US | disclosed |
| US-8859566-B2 | Substituted fused pyrimidine compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2014-10-14 | — | — | US | disclosed |
| US-8557765-B2 | Spatially-defined macrocycles incorporating peptide bond surrogates | TRANZYME PHARMA INC. (CA) | 2013-10-15 | — | — | US | disclosed |
| US-20120115864-A1 | Substituted Fused Pyrimidine Compounds | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-05-10 | — | — | US | disclosed |
| US-20090312540-A1 | SPATIALLY-DEFINED MACROCYCLES INCORPORATING PEPTIDE BOND SURROGATES | MNK 2011 LLC (F/K/A MALLINCKRODT INC.) | 2009-12-17 | — | — | US | disclosed |
| US-7550431-B2 | Spatially-defined macrocycles incorporating peptide bond surrogates | TRANZYME PHARMA INC. (CA) | 2009-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312540-A1 | SPATIALLY-DEFINED MACROCYCLES INCORPORATING PEPTIDE BOND SURROGATES | MLNR, GIPR, GRPR | POLB 4780/4885EPHX1 4394/4885TRPA1 1115/4885 |
| US-20120115864-A1 | Substituted Fused Pyrimidine Compounds | ADORA2A, ADORA1, ADORA3 | POLB 543/4885EPHX1 473/4885TRPA1 357/4885 |
| US-20150087643-A1 | Substituted Fused Pyrimidine Compounds | ADORA2A, ADORA1, ADORA3 | POLB 541/4885EPHX1 484/4885TRPA1 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.